Medtronic reports strongest revenue growth in a decade, shares hold near S&P 500 peer levels
26.06.2026 - 13:51:24 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 13:50.
Medtronic plc (IE00BTN1Y115) has just closed its fiscal 2026 with the strongest annual revenue growth the group has reported in roughly 10 years, underpinned by a marked acceleration in cardiovascular and diabetes devices, according to recent earnings coverage and consensus data. The shares trade on the NYSE under the ticker MDT and are part of the S&P 500 healthcare equipment cohort alongside peers such as Boston Scientific and Abbott Laboratories.
What the latest results show
On 3 June 2026 Medtronic posted its fiscal fourth-quarter numbers, delivering adjusted earnings per share of 1.55 US dollars, modestly above the consensus estimate of 1.54 dollars per share, as compiled by MarketBeat and other analyst platforms. Revenue in the quarter reached around 9.81 billion US dollars, up 9.9 percent year on year and ahead of the roughly 9.64 billion dollars that Wall Street had expected, reflecting solid procedural volumes and device uptake in core franchises.
Coverage from Ground News highlighted that cardiac ablation sales rose 78 percent globally and 124 percent in the United States, a striking expansion that contributed materially to the quarter’s beat and to Medtronic’s strongest top-line growth in a decade. Cardiovascular and diabetes segments were singled out as the main engines of the performance, pointing to continued momentum in chronic care devices and a constructive backdrop for procedure-linked revenues.
How analysts frame the stock
Analyst data compiled around the NYSE listing show that the MDT shares recently closed at about 80.54 US dollars on 25 June 2026, implying a market capitalization near 103 billion US dollars and placing the company firmly in the large-cap tier of the S&P 500 healthcare equipment & supplies industry. MarketBeat’s summary notes that the latest quarterly EPS of 1.55 dollars topped consensus by 0.01 dollars, indicating a result slightly above expectations but not a step-change versus prior guidance.
The technical overlay from TradingKey describes Medtronic’s price momentum score at 9.14, ranking 40th out of 203 names in the healthcare equipment & supplies industry and signaling a mid-pack but positive momentum profile compared with sector peers. According to that analysis, the shares are trading between a referenced resistance zone around 84.46 dollars and a support band near 74.94 dollars, a range that is presently seen as suitable for range-bound swing trading rather than a pronounced trend move.
All news and analysis on the Medtronic shares
Further articles, price data and background information on Medtronic plc are available in the dedicated topic section and on the company’s investor relations pages.
The business model behind the devices
Medtronic’s revenue base is diversified across cardiovascular, medical surgical, neuroscience and diabetes portfolios, with cardiac rhythm management and catheter-based ablation systems forming a core part of the cardiovascular franchise. The company generates income by selling implantable devices, consumables and capital equipment to hospitals and clinics, often supported by service contracts and long-term relationships with providers in the United States, Europe and key emerging markets.
Where the shares trade today
Medtronic shares (IE00BTN1Y115) trade on the NYSE under the symbol MDT at around 80.54 US dollars as of the 25 June 2026 close, according to TradingKey and StocksToTrade price data.
Key data on the Medtronic shares
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- WKN: A14M2J
- Ticker: MDT
- Trading venue: NYSE
- Price (as of 2026-06-25, 16:00): 80.54 US dollars
- Market cap: 103.07 billion US dollars (as of 2026-06-25)
- Sector / industry: Healthcare equipment & supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any security. All data are based on sources cited in the text and may change over time.
